Drug Profile
Research programme: complement factor D inhibitors - Achillion Pharmaceuticals
Latest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator Achillion Pharmaceuticals
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Complement factor D inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Chronic obstructive pulmonary disease
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 28 Feb 2020 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Inhalation)
- 28 Jan 2020 Achillion Pharmaceuticals has been acquired by Alexion Pharmaceuticals